Despite significant progress in cancer treatments, the benefits are not experienced equally across different socioeconomic groups.
C-106 by Vicore Pharma for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes